Lux Biosciences Initiates LUMINATE Pivotal Clinical Trials Of Its Next-Generation Calcineurin Inhibitor, LX211, In Uveitis

... Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company had begun treating patients in its LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TreatmEnt) pivotal clinical trial program of LX211, the company's next-generation calcineurin inhibitor. [click link for full article] ...